Pancreatic Cancer Clinical Trial
Official title:
Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery
Every patient undergoing surgery in the abdomen will experience temporary paralysis of bowel function. This study evaluates whether chewing gum can reduce the bowel paralysis after surgery in patients undergoing either esophageal resection or whipples procedure. Half the study population will receive chewing gum while the other half will act as control.
Every surgical procedure results in a temporary paralysis of bowel function. This condition
is named postoperative ileus (POI) and it is characterized by absence of intestine motility,
accumulation of gas and fluid inside the intestines and absence of flatus and defecation. It
results in nausea, vomiting, abdominal distension, pain and lowered tolerance towards intake
of fluid and solid foods. POI is the organism's reaction to the surgical trauma and it is
most often the single most important factor determining the length of patient admission.
Prolonged POI can also result in medical complications.
The length of POI following elective abdominal surgery is most often 3 to 6 days. Gradually
during this period the intestines regain their normal behavioral pattern. The colon is the
last segment to regain its motility which decides the patient's wellbeing. Therefore most
investigations of POI measure time from surgery to first flatus or defecation.
The cause of POI is found in the surgical trauma. When the abdominal wall and the peritoneum
are penetrated and the intestines exposed and handled, the immune system is activated. The
immune system creates an inflammatory response that inhibits the local neural pathways in
the intestines. The size of the immune response is related to the size of the surgical
procedure and the length of POI. Together with the overall hormonal surgical stress response
the inflammatory response creates a shift in the autonomous nervous system towards
sympathetic domination. This further inhibits bowel activity.
The intake of food activates parasympathetic activity and promotes bowel activity. Early
food intake following abdominal surgery, however, is often ill received by the patients
hence the above mentioned symptoms of POI. The early food intake can also worsen
complications following surgery such as anastomotic leakage. This is most pronounced with
anastomoses on the esophagus and stomach. Therefore abstinence from food intake is often
recommended in the immediate postoperative period.
Chewing of chewing gum following surgery can be perceived as placebo intake of food because
it also activates the parasympathetic nervous system and under normal conditions the
cephalic part of the digestion. Gum chewing does not, however, result in worsening of
potential surgical complications and it is generally well tolerated by the patients.
Postoperative gum chewing has been investigated and found effect full in the shape of
reduced POI following colorectal surgery, abdominal surgery on the aorta, bladder surgery,
and caesarian section.
The effect of gum chewing following surgery on the esophagus and the pancreas has to our
knowledge not yet been investigated.
With this study we wish to investigate the effect of gum chewing on POI in a patient
population undergoing either esophageal resection or pancreaticoduodenectomy (whipples
procedure) due to cancer in either the esophagus or the pancreas.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|